Business
LIXTE Biotechnology (LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape
LOS ANGELES, CA - March 23, 2026 (NEWMEDIAWIRE) - Experts working across oncology are exploring how different treatment approaches can work together to improve outcomes for cancer patients. One area drawing significant attention involves combining im...
About this update from Lixte Biotechnology Holdings, Inc.
[{"type":"text","content":"LOS ANGELES, CA - March 23, 2026 (NEWMEDIAWIRE) - Experts working across oncology are exploring how different treatment approaches can work together to improve outcomes for cancer patients. One area drawing significant attention involves combining immunotherapy with chemotherapy to help the immune system better recognize and attack tumors. LIXTE Biotechnology Holdings (NASDAQ: LIXT) is working within this emerging field through the development of its experimental compound LB-100, which is designed to enhance the effectiveness of existing cancer therapies by targeting biological mechanisms that influence immune recognition and tumor sensitivity to treatment.","length":665,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Recent research shows how chemotherapy and immunotherapy can complement each other when used together.","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"Within this evolving scientific landscape, LIXTE Biotechnology is pursuing a strategy designed to improve the performance of existing cancer treatments.","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"Inhibiting PP2A with LB-100 may increase tumor sensitivity to chemotherapy and radiation while also enhancing immune system activity against cancer cells.","length":154,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":408,"olType":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"Investor Brand Network","className":"","disableSlideshowImg":false,"size":{"original":{"width":1293,"height":507,"url":"https://media.zenfs.com/en/newsmediawire_165/24e5e865c170c2b5e9a7a0400b575fd2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/G2DGi3R0hbPlBxZDZhHCXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3Ng--/https://media.zenfs.com/en/newsmediawire_165/24e5e865c170c2b5e9a7a0400b575fd2","width":960,"height":376},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/JrcIiL04ET0fk6Rf6Zw0cQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NDI-/https://media.zenfs.com/en/newsmediawire_165/24e5e865c170c2b5e9a7a0400b575fd2","width":1200,"height":471}}},{"type":"text","content":"Interest in combining therapies stems from the reality that many cancers do not respond adequately to immunotherapy alone. Immune checkpoint inhibitors, which block proteins such as PD-1 or PD-L1 to enable immune cells to a...